Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib Plus Nimotuzumab in NSCLC
NCT01861223Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- May 2013
- Primary completion
- May 2015
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and nimotuzumab in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Primary endpoint: Maximal tolerated dose at 4 weeks. Status: unknown.
02
Drugs
afatinibnimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01861223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861223.